Abstract
Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer of the colon - rectum, that by orphan disease, it is now becoming an important paradigm of scientific innovations and concepts.
Survival of patients with metastatic colorectal cancer (m-CRC) has been significantly improved with the introduction of the monoclonal antibodies that have as target the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR).
The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction. This pathway is up -regulated in many tumours. Blockade of this pathway with anti-PD-1 and anti-PD-L1 agents has led to remarkable clinical responses in patients affected by many different types of cancer.
The aim of this review is to evaluate the effects of addiction of biological agents to standard chemotherapy in the treatment of m-CRC.
We can say that, among the various treatment options, the challenge of the future will be a better selection of the population, to ensure the best possible benefit from treatment with anti-VEGF drugs or anti-EGFR and a careful and customized planning of the therapeutic strategy for each patient.
Keywords: Colorectal cancer, monoclonal antibodies, target therapy, treatment, anti-VEGF drugs, anti-EGFR.
Current Cancer Drug Targets
Title:Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives
Volume: 18 Issue: 5
Author(s): Anna Nappi, Massimiliano Berretta, Carmela Romano, Salvatore Tafuto, Antonino Cassata, Rossana Casaretti, Lucrezia Silvestro, Chiara De Divitiis, Lara Alessandrini, Francesco Fiorica, Alessandro Ottaiano and Guglielmo Nasti*
Affiliation:
- Medical Oncology, Abdominal Department, National Cancer Institute G. Pascale Foundation, 80131 Napoli,Italy
Keywords: Colorectal cancer, monoclonal antibodies, target therapy, treatment, anti-VEGF drugs, anti-EGFR.
Abstract: Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer of the colon - rectum, that by orphan disease, it is now becoming an important paradigm of scientific innovations and concepts.
Survival of patients with metastatic colorectal cancer (m-CRC) has been significantly improved with the introduction of the monoclonal antibodies that have as target the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR).
The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction. This pathway is up -regulated in many tumours. Blockade of this pathway with anti-PD-1 and anti-PD-L1 agents has led to remarkable clinical responses in patients affected by many different types of cancer.
The aim of this review is to evaluate the effects of addiction of biological agents to standard chemotherapy in the treatment of m-CRC.
We can say that, among the various treatment options, the challenge of the future will be a better selection of the population, to ensure the best possible benefit from treatment with anti-VEGF drugs or anti-EGFR and a careful and customized planning of the therapeutic strategy for each patient.
Export Options
About this article
Cite this article as:
Nappi Anna, Berretta Massimiliano, Romano Carmela, Tafuto Salvatore, Cassata Antonino, Casaretti Rossana, Silvestro Lucrezia, Divitiis De Chiara, Alessandrini Lara, Fiorica Francesco, Ottaiano Alessandro and Nasti Guglielmo*, Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009617666170209095143
DOI https://dx.doi.org/10.2174/1568009617666170209095143 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Curcumin Targets in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation
Pharmaceutical Nanotechnology Mesenchymal Stem Cells Regulate Cytoskeletal Dynamics and Promote Cancer Cell Invasion Through Low Dose Nitric Oxide
Current Molecular Medicine Relevance of Micrometastases and Targeting the Bone Marrow Niche with Zoledronic Acid in Breast Cancer
Current Cancer Therapy Reviews The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design The Diagnostic Utility of Pleural Fluid Tests in Clinical Practice
Current Respiratory Medicine Reviews Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Cyclophilin function in Cancer; lessons from virus replication
Current Molecular Pharmacology Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets MicroRNAs and Chronic Inflammation Contribution to Gastrointestinal Integrity
Current Medicinal Chemistry Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)
Current Pharmaceutical Design Tumor Biomarkers: Clinical Utility, Promises and Problems
Applied Clinical Research, Clinical Trials and Regulatory Affairs Artificial Intelligence Techniques for Colorectal Cancer Drug Metabolism: Ontologies and Complex Networks
Current Drug Metabolism microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews Drug Discovery by Targeting Mutant KRAS
Current Topics in Medicinal Chemistry The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment
Current Cancer Therapy Reviews